OCULAR THERAPEUTIX, INC Cost of Goods Sold (Deprecated 2018-01-31)
OCULAR THERAPEUTIX, INC (OCUL) reported Cost of Goods Sold (Deprecated 2018-01-31) of $457.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-03-08
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $113.00K, a 11.02% decline year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $125.00K, a 11.61% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $104.00K, a 0.95% decline year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $115.00K, a 16.16% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $457.00K, a 3.16% increase from fiscal 2016.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $443.00K, a 38.87% increase from fiscal 2015.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $319.00K, a 250.55% increase from fiscal 2014.
- OCULAR THERAPEUTIX, INC cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $91.00K.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $238.00K derived: sum of 2 quarters · filed 2018-03-08 | $342.00K derived: sum of 3 quarters · filed 2018-03-08 | $457.00K 10-K · filed 2018-03-08 |
| 2017-09-30 | $125.00K 10-Q · filed 2017-11-07 | $229.00K derived: sum of 2 quarters · filed 2017-11-07 | $344.00K 10-Q · filed 2017-11-07 | $471.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $104.00K 10-Q · filed 2017-08-08 | $219.00K 10-Q · filed 2017-08-08 | $346.00K derived: sum of 3 quarters · filed 2018-03-08 | $458.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $115.00K 10-Q · filed 2017-05-05 | $242.00K derived: sum of 2 quarters · filed 2018-03-08 | $354.00K derived: sum of 3 quarters · filed 2018-03-08 | $459.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $239.00K derived: sum of 2 quarters · filed 2018-03-08 | $344.00K derived: sum of 3 quarters · filed 2018-03-08 | $443.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $112.00K 10-Q · filed 2017-11-07 | $217.00K derived: sum of 2 quarters · filed 2017-11-07 | $316.00K 10-Q · filed 2017-11-07 | $408.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $105.00K 10-Q · filed 2016-08-09 | $204.00K 10-Q · filed 2017-08-08 | $296.00K derived: sum of 3 quarters · filed 2018-03-08 | $387.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $99.00K 10-Q · filed 2017-05-05 | $191.00K derived: sum of 2 quarters · filed 2018-03-08 | $282.00K derived: sum of 3 quarters · filed 2018-03-08 | $362.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $183.00K derived: sum of 2 quarters · filed 2018-03-08 | $263.00K derived: sum of 3 quarters · filed 2018-03-08 | $319.00K 10-K · filed 2018-03-08 |
| 2015-09-30 | $91.00K 10-Q · filed 2016-11-09 | $171.00K derived: sum of 2 quarters · filed 2016-11-09 | $227.00K 10-Q · filed 2016-11-09 | $257.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $80.00K 10-Q · filed 2016-08-09 | $136.00K 10-Q · filed 2016-08-09 | $166.00K derived: sum of 3 quarters · filed 2017-03-10 | $198.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $56.00K 10-Q · filed 2016-05-10 | $86.00K derived: sum of 2 quarters · filed 2017-03-10 | $118.00K derived: sum of 3 quarters · filed 2017-03-10 | $138.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $62.00K derived: sum of 2 quarters · filed 2017-03-10 | $82.00K derived: sum of 3 quarters · filed 2017-03-10 | $91.00K 10-K · filed 2017-03-10 |
| 2014-09-30 | $32.00K 10-Q · filed 2015-11-10 | $52.00K derived: sum of 2 quarters · filed 2015-11-10 | $61.00K 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $20.00K 10-Q · filed 2015-08-10 | $29.00K 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $9.00K 10-Q · filed 2015-05-15 | |||
| 2012-12-31 | $7.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |